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Abstract
Background: The search for essential tremor (ET) genes is active, and it is only a matter of time before genetic tests become available. Genetic testing preferences
in families have been studied in numerous other neurological disorders but there are no published data about ET.
Methods: We surveyed 34 ET probands and their relatives (43 affected, 28 unaffected) enrolled in our Family Study of Essential Tremor to assess their interest in
genetic testing. We examined whether clinical factors influenced their interest in testing. Clinical utility (‘‘Your physician will be able to use the information obtained
to improve your care’’) and penetrance (‘‘How likely an individual who carries an ET gene is to develop ET’’) were defined for participants.
Results: Interest in genetic testing was high in ET families (90/105 [85.7%]). There was a significant difference between affected (including probands and affected
relatives) and unaffected relatives in terms of their interest in genetic testing, with the former being more interested (70/77 [90.9%] vs. 20/28 [71.4%] p 5 0.04).
Participants were more likely to want testing in the scenarios with high clinical utility; disease penetrance was not a determining factor (all p , 0.05). Sixteen
hypothetical factors were identified that might influence a participant’s decision to undergo genetic testing for ET.
Discussion: Interest in genetic testing was high in ET families. While genetic testing is not currently available for ET, the hunt for ET genes is ongoing, and this is
a highly familial disorder. Understanding genetic testing preferences will greatly aid clinicians once a genetic test becomes available.
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Introduction
Essential tremor (ET) is the most common tremor disorder and
among the most common neurological disorders.1–4 Tremor in ET
typically occurs in the hands and arms during voluntary movements
and may eventually affect other body regions such as the head, jaw,
and voice.5
ET is highly familial. Familial aggregation data show that first-
degree relatives of ET cases are approximately five times more likely to
develop ET than are first-degree relatives of control subjects.6 ET has
traditionally been characterized as having a Mendelian (autosomal
dominant) mode of inheritance.7–10 However, recent evidence also
suggests that ET could be a complex disease.11
The yield in genetic studies of ET has been somewhat limited,
however, due to a variety of issues, including phenotypic and genotypic
heterogeneity.10 As a result, no causative mutations have been repro-
ducible and a specific genetic test is not currently available.8–10
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The lack of definitive clinical diagnostic criteria or a specific biomarker
unique to ET has also presented obstacles in candidate gene studies.8–10
Even so, the search for ET genes is active, and it is only a matter of
time until gene discovery efforts are more successful and genetic tests
become available.8
Genetic testing preferences in families have been studied in numerous
other neurological disorders such as epilepsy, Huntington’s disease,
and Alzheimer’s disease, with occasional unexpected results.12–14
Despite the fact that it is highly familial, the literature available on
genetic testing preferences in ET families is non-existent. Indeed, there
are no published data on 1) genetic testing preferences of patients with
ET or 2) how various demographic or clinical factors might influence a
patient’s decision to decide to undergo genetic testing.
We surveyed the preferences of individuals currently enrolled in
our Family Study of Essential Tremor (FASET II) to assess their
willingness to undergo genetic testing. We also examined whether
clinical and demographic factors influenced this willingness.
Methods
Study sample
The study sample comprised ET probands and their first- and
second-degree affected and unaffected relatives enrolled in FASET II
(September 2015 to present). Families were primarily recruited with
targeted advertisements posted on the International Essential Tremor
Foundation (IETF) and the Tremor Action Network (TAN) websites.
These families met the initial criteria of having 1) a proband whose ET
diagnosis had been assigned by a doctor and whose age of tremor onset
was #40 years (later changed to #50 to be more inclusive), 2) at least
three reportedly affected family members and at least two reportedly
unaffected family members, and 3) no family history of dystonia or
Parkinson’s disease.
Study design and sample size
As part of FASET II, each participant underwent a 3-hour in-person
evaluation that included signed informed consent, clinical question-
naires, a videotaped neurological examination, and phlebotomy.15,16
These evaluations were conducted by one of four trained research
personnel (K.V.N., J.P., K.P.C., N.H.). The severity of postural and
kinetic tremors on videotaped neurological examination was rated (0–3)
by a senior movement disorders neurologist (E.D.L.), and published
diagnostic criteria for ET (moderate or greater amplitude kinetic tremor
[tremor rating >2] during three or more videotaped activities or a
head tremor in the absence of Parkinson’s disease or other known
causes) were applied.7,17
Each enrollee was also eligible to participate in an additional genetic
testing survey, which was the focus of the current analyses. The survey
was posted from August 8, 2016, to January 15, 2017. From a pool
of 122 enrollees, 105 (86.1%) agreed to participate. This sample size
was of similar or greater magnitude to those used in prior studies of
Alzheimer’s disease and Huntington’s disease with similar aims.12,14
All study procedures and surveys were approved by the Yale University
Institutional Review Board.
Genetic testing survey
General comments. The genetic testing survey was completed online
(Qualtrics, yalesurvey.qualtrics.com) and included demographic ques-
tions, family history questions, questions about tremor, a section that
assessed interest in genetic testing in four genetic testing scenarios (see
below), and a section that assessed whether each of 21 hypothetical
factors such as ‘‘The results could improve your health/healthcare’’
might affect the participant’s decision to undergo genetic testing.
Demographic questions. The survey included demographic questions
(age, gender, ethnicity, religion, education, marital status, and number
of children) (Table 1). These could influence genetic testing preferences.
Family history, tremor history and question about genetic testing.
Each participant endorsed whether they had tremor or not and how
many family members were reportedly affected. If tremor was endorsed,
follow-up questions on severity and duration of tremor and modes of
treatment were included. To assess the level of interest in genetic testing,
the survey included a question that specifically asked whether each
participant would ‘‘be interested in genetic testing for ET if such a test
were available’’ (Table 2).
Four genetic testing scenarios. Each participant was given a definition
bank that defined certain terms to be used in four genetic testing
scenarios that followed (Figures 1 and 2). These terms were 1) clinical
utility (‘‘Your physician or neurologist will be able to use the information
obtained to improve your treatment or care’’) and 2) penetrance (‘‘How
likely an individual who carries an ET gene is to develop ET’’) alongside
a graphic denoting 100% penetrance (everyone who carries the gene will
develop ET) vs. 50% penetrance (only one-half of the individuals who
carry the gene will develop ET).
Each of the four genetic testing scenarios comprised a different com-
bination of clinical utility and penetrance: clinical utility and penetrance,
each was 100% (Scenario 1); clinical utility and penetrance, each was
50% (Scenario 2); no clinical utility and penetrance, 100% (Scenario 3);
and no clinical utility and penetrance, 50% (Scenario 4). Participants
were asked to indicate whether in each scenario they would decide to
undergo genetic testing. To do so, participants used a five-point
Likert scale (definitely yes, probably yes, don’t know, probably no,
definitely no).
Twenty-one hypothetical factors that could influence decision to
undergo testing. We also assessed whether each of 21 hypothetical
factors might influence a participant’s decision to undergo genetic
testing (Table 3). For analytical purposes, we grouped these factors
into four categories: 1) the factor positively impacts desire for genetic
testing (e.g., ‘‘The results could improve your health or healthcare’’),
2) the factor negatively impacts desire for genetic testing (e.g., ‘‘Impact
on your career’’, ‘‘An effect on insurance coverage’’), 3) beliefs, family,
and future, which could have positive or negative impact (e.g., ‘‘Your
religious, cultural, and/or spiritual beliefs’’, ‘‘Your decision about
having children’’), and 4) medical implications (‘‘Having test results to
share with your doctor’’, ‘‘Your treatment options for essential tremor’’).
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At least a bachelor’s degree 68 (64.7)





Never married 11 (10.5)
Children
None 19 (18.1)




Family history of ET
‘‘I am the only person with essential tremor’’ 1 (1.0)
‘‘Yes, myself and one other person’’ 3 (2.9)
‘‘Yes myself and two or more people’’ 73 (69.5)
‘‘Yes my family but not me’’ 28 (26.7)
Tremor duration (years) 30.5 ¡ 20.8
Form of ET treatment
‘‘I do not treat it in any way’’ 42 (40.0)
‘‘I take medication when needed’’ 5 (4.8)
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How each of the 21 factors would affect a participant’s decision to
undergo genetic testing was measured on a five-point Likert scale (much
less likely to want testing, somewhat less likely to want testing, no effect
on my desire for testing, somewhat more likely to want testing, much
more likely to want testing).
Statistical analysis
Statistical analyses were carried out using IBM SPSS Statistics
(Version 24). We used chi-square tests to compare the two genders
and the three participant types (proband, affected relative, unaffected
Table 1. Continued
Characteristic Data
‘‘I take medication daily’’ 25 (23.8)
‘‘I had surgery to treat it and take medication’’ 5 (4.8)
‘‘I do not have ET’’ (unaffected relatives) 28 (26.7)
Abbreviation: ET, Essential Tremor.
All values are mean ¡ standard deviation or number (percentage).
1Some individuals have more than one type (e.g., biological and adopted).
Table 2. ‘‘Would you be Interested in Genetic Testing for ET if such a Test were Available’’
Yes No Not Sure p (Chi-Square Test)
Entire sample 90 (85.7) 2 (1.9) 13 (12.4)
Gender Male 40 (87.0) 1 (2.2) 5 (4.8) 0.911
Female 50 (84.7) 1 (1.7) 8 (13.6)
Participant type Proband 32 (94.1) 1 (2.9) 1 (2.9) 0.082
0.043
Affected relative 38 (88.4) 0 (0.0) 5 (11.6)
Unaffected
relative
20 (71.4) 1 (3.6) 7 (25.0)
All values represent number (row percentage).
1There was no difference between gender and desire for genetic testing.
2Comparing probands, affected relatives, and unaffected relatives.
3Comparing affected (probands + affected relatives) and unaffected relatives.
Figure 1. Genetic Testing Preferences of Affecteds in Four Scenarios
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relative) in their responses to the question ‘‘Would you be interested in
genetic testing for ET if such a test were available?’’ (Table 2). Using
McNemar’s tests, we compared responses across the four genetic
testing scenarios. For these analyses, we collapsed the five responses
into dichotomous categories (definitely yes/probably yes vs. definitely
no/probably no/don’t know). We first performed these analyses in
affected individuals (i.e., probands and affected relatives) and then
repeated these analyses in unaffected relatives (Figures 1 and 2).
In order to assess the significance of the 21 hypothetical factors that
might influence a participant’s decision to undergo genetic testing we
coded each of the possible responses into numerical values. Negative
responses were coded as –2 for ‘‘much less likely to want testing’’ and
–1 for ‘‘somewhat less likely to want testing’’. ‘‘No effect on my desire for
testing’’ was a neutral response and therefore coded as 0. The positive
responses were accordingly coded as 1 for ‘‘somewhat more likely to
want testing’’ and 2 for ‘‘much more likely to want testing’’. We
calculated the mean value of each of the 21 responses to determine
overall positive vs. negative effect (Table 3). Coding the responses in such
a way allowed us to distinguish factors with a positive effect reflected by
a positive mean value and factors with a negative effect reflected by a
negative mean value. We then performed a one-sample t-test to detect
significance from a fixed value of zero. Given the number of comparisons
(n 5 21), a Bonferroni correction was applied (0.05/21 5 0.0024), with
significance set at p , 0.0024 (Table 3).
Lastly, to analyze any potential association between demographic
and other clinical factors and interest in genetic testing, we used
generalized estimating equations to determine whether each of these
factors predicted the answer to ‘‘Would you be interested in genetic
testing if such a test were available?’’ (Table 4). For some variables, we
collapsed categories: for religion we compared ‘‘Catholic’’ with ‘‘non-
Catholic’’. For marital status, we compared ‘‘ever married’’ (married,
divorced, separated, widowed) with ‘‘never married’’. Lastly, for the
presence of children, we included biological children only (omitting
adopted and step-children) and compared with none. These analyses
yielded beta and p values.
Results
Demographic and clinical characteristics
The 105 participants comprised 34 (32.4%) probands, 43 (41.0%)
affected relatives, and 28 (26.6%) unaffected relatives (Table 1). Forty-six
(43.8%) were male and nearly all (104 or 99.0%) were non-Hispanic
white. The mean age was 59.3¡ 16.1 years (range 21–90 years). Nearly
two-thirds (64.7%) had at least a bachelor’s degree (Table 1).
Question about genetic testing
To assess general interest in genetic testing for ET we asked each
participant: ‘‘Would you be interested in genetic testing for ET if such
a test were available?’’ (Table 2). Interest in genetic testing was high in
families (90/105 [85.7%], Table 2). There was a marginal difference
between probands, affected relatives, and unaffected relatives in their
interest in genetic testing (Table 2, p 5 0.08). However, there was a
significant difference between affected relatives (including probands
and affected relatives) and their unaffected relatives in terms of their
interest in genetic testing, with the former being more interested (70/
77 [90.9%] vs. 20/28 [71.4%], p 5 0.04, Table 2).
Interest in genetic testing in four genetic testing scenarios
Affected individuals were more likely to want testing in the scenarios
with clinical utility; disease penetrance was not a determining factor,
and the differences were not significant. Thus, among 77 affected
persons (i.e., probands and affected relatives), 69 (89.6%) said they
would definitely or probably want genetic testing in Scenario 1 (clinical
utility and penetrance, each were 100%) vs. only 56 (72.7%) in
Scenario 3 (no clinical utility and 100% penetrance) (McNemar’s test
p , 0.001). Similarly, in Scenario 2 (clinical utility and penetrance,
each were 50%), 68 (88.3%) of 77 affected individuals said they would
definitely or probably want genetic testing vs. only 51 (66.2%) in
Scenario 4 (no clinical utility and penetrance, 50%) (McNemar’s test
p , 0.001) (Figure 1).
Figure 2. Genetic Testing Preferences of Unaffecteds in Four Scenarios
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Akin to their affected counterparts, the 28 unaffected relatives were
more likely to want testing in the scenarios with clinical utility whereas
disease penetrance was not a determining factor: 27 (96.4%) in
Scenario 1 vs. 18 (64.3%) in Scenario 3 (McNemar’s test p 5 0.004),
and 25 (89.3%) in Scenario 2 vs. 15 (53.6%) in Scenario 4 (McNemar’s
test p 5 0.002) (Figure 2).
Twenty-one hypothetical factors that could influence decision to
undergo testing
In order to assess the significance of the 21 hypothetical factors that
might influence a participant’s decision to undergo genetic testing we
coded each of the possible responses into numerical values. We ranked
the factors by the mean response such that ‘‘The results could improve
your health or healthcare’’ was the most positive factor with a mean
of 1.67 and ‘‘The test is not affordable’’ was the most negative factor
with a mean of –1.01 (Table 3). We conducted a one-sample t-test with
Bonferroni correction in order to test the statistical significance of
each factor. We found a factor to be significant if the p-value was less
than 0.0024. A large number of factors (n 5 16 that were significant)
were identified that might influence a participant’s decision to undergo
genetic testing (Table 3).
As noted above, we grouped the 21 hypothetical factors into four
categories. As expected, factors in Category 1 (i.e., the factor positively
impacts desire for genetic testing: ‘‘The results could improve your
Table 3. Twenty-one Hypothetical Factors that Might Influence a Participant’s Decision to Undergo Genetic Testing
Significance Mean Category
The results could improve your health or health care 0.000* 1.671 1
Learn that changing your behavior could reduce symptoms 0.000* 1.651 1
Learn if ET is caused by a specific gene 0.000* 1.581 1
Determine if your children are at risk 0.000* 1.541 1
Learn some of your genetic information 0.000* 1.501 1
The test is highly accurate 0.000* 1.43 2
Your treatment options for ET 0.000* 1.39 4
The test is affordable 0.000* 1.30 2
Having test results to share with your doctor 0.000* 1.17 4
Your decision to opt for surgery to treat ET 0.000* 0.58 4
An effect on your future plans 0.002 0.50 3
Your family’s reaction to genetic testing 0.000* 0.44 3
Having your blood drawn for testing 0.000* 0.35 4
Your decision about having children 0.000* 0.25 3
Impact your career 0.042 0.23 2
Your religious, cultural, and/or spiritual beliefs 0.004 0.23 3
Your decision about marriage 0.000* 0.20 3
Affect your insurance 0.411 –0.112 2
Impact your privacy 0.054 –0.222 2
The test is less accurate 0.000* –0.512 2
The test is not affordable 0.000* –1.012 2
Abbreviation: ET, Essential Tremor.
*Statistically significant, p , 0.0024.
1Highest ranked positive effect factors.
2Negative effect factors.
Naranjo KV, Park J, Chen KP, et al. Genetic Testing in Essential Tremor
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health or healthcare’’) had higher means across all participants. For
Category 2 (i.e., the factor negatively impacts desire for genetic testing:
‘‘An effect on insurance coverage’’), the responses had a negative
mean. Participants cared more about the affordability of a test rather
than its accuracy: ‘‘The test is not affordable’’ had a mean of –1.01 vs.
–0.51 for ‘‘The test is less accurate’’ (Table 3).
Responses to Category 3 (i.e., beliefs, family, and future: ‘‘Your
religious, cultural, and/or spiritual beliefs’’, ‘‘Your decision about
having children’’) and Category 4 (i.e., medical implications: ‘‘Having
test results to share with your doctor’’, ‘‘Your treatment options for
essential tremor’’) showed positive averages overall. It should be noted
that ‘‘Your treatment options for ET’’ could have been ranked high
among factors because our sample contained more affected than
unaffected relatives. Alternatively, it might be the case that all family
members are equally interested in viable treatment options.
Demographic and clinical predictors influencing desire to
undergo genetic testing
We were interested in learning whether demographic and other
clinical factors were predictors for desire to undergo genetic testing.
We evaluated the answers to ‘‘Would you be interested in genetic
testing if such a test were available?’’ in a dichotomous manner such
that the responses were analyzed as ‘‘yes’’ vs. ‘‘no’’/‘‘unsure’’. Factors
we considered were gender, religion, education, marital status,
diagnosis status (affected vs. unaffected), tremor duration, presence
of biological children, and age as possible predictors. Only diagnostic
status (affected vs. unaffected) was statistically significant (Table 4).
Discussion
Currently, the only tool for diagnosing and phenotyping ET is
clinical. There are no serum or imaging biomarkers for ET, and
clinical overlap with Parkinson’s disease and dystonia further com-
plicates diagnosis.18 Therefore gene identification could aid consider-
ably in ET diagnosis in ET families. Furthermore, gene identification
will eventually be an issue for ET families, among whose members may
wish to determine their gene status, especially if ET is regarded as a
risk factor for dementia or Parkinson’s disease and if it is viewed as
associated with an increased risk of mortality.19–22 We surveyed the
preferences of individuals currently enrolled in our family study of ET
to assess their willingness to undergo genetic testing.
Genetic testing survey responses from patients at risk for Huntington’s
disease showed, before genetic testing was available, a high interest in
future genetic testing to verify status. However, once a test became
available, the interest was far lower than expected (,15%).12,22 These
data can partly be explained by the fact that a positive Huntington’s
disease genetic testing result has dire prognostic implications. Our data
also show that, before genetic testing is available, individuals with a
family history of ET were highly interested in genetic testing. Indeed,
90.9% of affected individuals (probands and affected relatives) and
71.4% unaffected relatives expressed interest in genetic testing with the
information currently available to them.
Affected individuals were more interested in genetic testing than
were unaffected individuals (90.9% vs. 71.4%, p 5 0.04). This could
relate to the fact that these individuals are searching for knowledge or
interventions that could impact on their disease either at present or in
the foreseeable future.
We also demonstrated that individuals, whether affected or unaffected,
were more likely to want testing in the scenarios with clinical utility;
disease penetrance was not a determining factor. This was similar to
the findings in a survey of epilepsy.13 In diseases with symptomatic
treatments, clinical utility may be translated to better treatment or
clinical management options.
A number of hypothetical factors negatively impact desire for
genetic testing: both affected and unaffected relatives cared quite a bit
about the affordability of a test. In a time of expensive and increasingly
sophisticated testing and treatment options, this is not unexpected.
As would be expected, all the hypothetical factors in Category 1
(‘‘The results could improve your health/ healthcare’’, ‘‘Knowing
ET is caused by a specific gene’’, ‘‘Changing your behavior could
reduce symptoms’’, ‘‘Knowing if your children are at risk’’, and
‘‘Learn some of your genetic information’’), positively impacted
desire for genetic testing.
This study had several limitations. First, the sample size was modest;
despite this, the sample size was of similar or greater magnitude to
those used in prior studies of Alzheimer’s disease and Huntington’s
disease with similar aims.12,14 Indeed, we detected significant effects
across analyses. Despite this, future studies with larger samples would
be beneficial. Second, ours was a very educated cohort (64.7% of
participants had a bachelor’s degree or higher). Our study heavily
recruited patients from patient-centered organizations (IETF and
TAN) and patients with long-standing disease; hence, our findings
of this study might not be generalizable to cohorts with different
characteristics recruited through different means. Third, we asked our
Table 4. Demographic and Clinical Predictors Influencing Desire
to Undergo Genetic Testing








Tremor duration 0.015 0.51
Biological children –0.375 0.59
Age 0.010 0.65
1Statistically significant.
These analyses utilized generalized estimating equations.
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study subjects about hypothetical testing situations. Their responses,
when actually confronted with a testing situation, could differ. Further-
more, we did not elicit their desire to undergo genetic testing to
enhance science and research.
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